ストックスクリーナーアプリを入手
0.1482
1.92%
-0.0029
アフターアワーズ：
.15
0.0018
+1.21%
In 8 Bio Inc (INAB) 最新ニュース
High Growth Tech Stocks Including ABL Bio To Watch - Yahoo
ABL Bio lands $2.8 billion license-out deal with GSK - KED Global
GRI Bio Reports Encouraging Interim 2-Week Safety Results - GlobeNewswire
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) - Yahoo Finance
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan - GlobeNewswire
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Yahoo Finance
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Globe and Mail
Healthcare Spotlight: Climb Bio Takes Center Stage at Major Needham Conference - Stock Titan
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - Quantisnow
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Quantisnow
Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Kronos Bio Inc (KRON) Q4 2024 Earnings: EPS Misses at -$0.43, Re - GuruFocus.com
GRI Bio Reports Full Year 2024 Financial Results and - GlobeNewswire
Short Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 26.8% - Defense World
Analysts Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $8.33 - Defense World
Gossamer Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders - Joplin Globe
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule - GlobeNewswire
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts - Yahoo Finance
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Q32 Bio Inc expected to post a loss of $1.51 a shareEarnings Preview - TradingView
Nuvation Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Yahoo Finance
Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Global Nucleic Acid Amplification Testing Market to Grow Rapidly at an ~8% CAGR by 2032 | DelveInsight - GlobeNewswire
Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy - Defense World
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - Yahoo Finance
What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - Benzinga
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - GlobeNewswire Inc.
KALA BIO Announces Chief Executive Officer Transition - GlobeNewswire
Plug Power (NASDAQ:PLUG) Enters Into Standby Equity Purchase Agreement with YA II PN, LTD - Defense World
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Mustang Bio Closes $8 Million Public Offering - citybiz
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Mustang Bio Announces Closing of $8 Million Public Offering - The Manila Times
Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development - Nasdaq
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - The Manila Times
Bluebird bio Inc (NASDAQ: BLUE) Now Carries A 12-Month Price Target Of $25. - Marketing Sentinel
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Quantisnow
Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewswire
Capital Raise Alert: Mustang Bio Secures Fresh $8M Funding Through Strategic Share & Warrant Offering - Stock Titan
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Quantisnow
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
0.48%
大文字化:
|
ボリューム (24 時間):